MiRNAs Predict the Prognosis of Patients with Triple Negative Breast Cancer: A Meta-Analysis

被引:16
|
作者
Liu, Yanli [1 ]
Zhang, Yuchao [2 ]
Li, Qingfu [3 ]
Li, Junfang [2 ]
Ma, Xiaotian [2 ]
Xing, Jinfang [2 ]
Rong, Shouhua [2 ]
Wu, Zhong [4 ]
Tian, Yuan [2 ]
Li, Jing [2 ]
Jia, Liting [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 3, Dept Reprod Ctr, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 3, Dept Clin Lab, Zhengzhou, Peoples R China
[3] Peoples Hosp Henan Prov, Dept Stomatol, Zhengzhou, Peoples R China
[4] Henan Univ, Women & Infants Hosp Zhengzhou, Dept Clin Lab, Zhengzhou, Peoples R China
来源
PLOS ONE | 2017年 / 12卷 / 01期
关键词
SUPPRESSES TUMOR PROLIFERATION; HIGH EXPRESSION; POOR-PROGNOSIS; CIRCULATING MICRORNAS; SURVIVAL; BIOMARKERS; SIGNATURE; PATTERNS; MIR-21;
D O I
10.1371/journal.pone.0170088
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose miRNAs are stable and can be extracted from tissues, blood and other body fluid without degradation. miRNAs are abnormally expressed in the presence of a pathological status, including cancer. Therefore, miRNAs are ideal biomarkers for cancer diagnosis and prognosis. Patients with triple negative breast cancer (TNBC) suffer the worst prognosis, although great efforts have been made. Many studies have investigated the role of miRNAs in predicting the outcomes of TNBC patients for better adjustment of treatment. However, results were inconsistent. Thus, we performed a meta-analysis to summarize the published studies for conclusive results. Methods Eligible studies from different database were retrieved from the online databases, and we used STSTA 12.0 to analysis the prognostic role of miRNAs in triple negative breast cancer. Results Overall high miRNA expression indicated a worse survival with HR value of 1.78 (95% CI: 0.97-3.25). However, subtotal HRs of oncogenic miRNAs and tumor suppressive miRNAs were 2.73 (95% CI: 2.08-3.57; P<0.001) and 0.44 (95% CI: 0.21-0.90; P = 0.024), respectively, and no heterogeneity was observed within the subgroups. Conclusions The miRNAs showed a slightly stronger prognostic value for disease-free survival, relapse-free survival and distant metastasis-free survival compared to the overall survival of TNBC patients. Circulating miRNAs could serve as potential biomarkers for the prognosis of TNBC patients and need further investigation.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Recurrence and Survival in Patients With Triple Negative Breast Cancer Receiving Statins: A Systematic Review and Meta-Analysis
    Brown, Zachary M.
    McKechnie, Tyler
    Lovrics, Olivia
    Eskicioglu, Cagla
    Parvez, Elena
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S208 - S208
  • [22] Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis
    Fancellu, A.
    Houssami, N.
    Sanna, V
    Porcu, A.
    Ninniri, C.
    Marinovich, M. L.
    BRITISH JOURNAL OF SURGERY, 2021, 108 (07) : 760 - 768
  • [23] Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis
    Wang, Jin
    Xie, Xiaoming
    Wang, Xi
    Tang, Jun
    Pan, Qingqing
    Zhang, Yefan
    Di, Mengyang
    SURGICAL ONCOLOGY-OXFORD, 2013, 22 (04): : 247 - 255
  • [24] The Prognosis of Metaplastic Breast Cancer Patients Compare to Triple-Negative Breast Cancer Patients
    Cho, D. H.
    Jang, J. H.
    Lee, S. K.
    Choi, M-Y
    Koo, M. Y.
    Hur, S. M.
    Bae, S. Y.
    Kim, S. M.
    Choe, J-H
    Lee, J. E.
    Kim, J-H
    Kim, J. S.
    Nam, S. J.
    Yang, J-H
    CANCER RESEARCH, 2010, 70
  • [25] Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
    Xun, Xueqiong
    Ai, Jun
    Feng, Fuhui
    Hong, Pan
    Rai, Saroj
    Liu, Ruikang
    Zhang, Baowen
    Zhou, Yeming
    Hu, Huiyong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [26] Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis
    Hercules, Shawn M.
    Alnajar, Meena
    Chen, Chen
    Mladjenovic, Stefan M.
    Shipeolu, Bolade Ajarat
    Perkovic, Olga
    Pond, Greg R.
    Mbuagbaw, Lawrence
    Blenman, Kim R. M.
    Daniel, Juliet M.
    BMJ OPEN, 2022, 12 (05): : e055735
  • [27] Platinum is essential in neoadjuvant treatment of triple negative breast cancer: A network meta-analysis
    Li, Junjie
    Chen, Li
    Tan, Wei
    Qi, Fang
    Zhang, Yang
    Wang, Zhonghua
    Shao, Zhimin
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Meta-analysis of genomic aberrations identified in CTCs andctDNA in triple negative breast cancer
    Howard, Kellie
    Austin, Sharon
    Lo, Fang Yin
    Ramirez, Arturo
    Boles, Debbie
    Pruitt, John
    Mahen, Elisabeth
    Collins, Heather
    Leonti, Amanda
    Maassel, Lindsey
    Subia, Christopher
    Saloranta, Tuuli
    Christopherson, Nicole
    Deutsch, Kerry
    Stilwell, Jackie
    Kaldjian, Eric
    Dorschner, Michael
    Blau, Sibel
    Blau, Anthony
    Eisenberg, Marcia
    Anderson, Steven
    Madan, Anup
    CANCER RESEARCH, 2016, 76
  • [29] Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
    Zhang, Wei
    Li, Emma
    Wang, Lily
    Lehmann, Brian D. D.
    Chen, X. Steven
    CANCERS, 2023, 15 (08)
  • [30] Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
    Chen, Haixia
    Wu, Jianming
    Zhang, Zhihong
    Tang, Yong
    Li, Xiaoxuan
    Liu, Shuangqing
    Cao, Shousong
    Li, Xianzhu
    FRONTIERS IN PHARMACOLOGY, 2018, 9